NCCN Guidelines® Insights: Prostate cancer early detection, version 1.2023 Featured updates to the NCCN guidelines Guidelines


Authors: Moses, K. A.; Sprenkle, P. C.; Bahler, C.; Box, G.; Carlsson, S. V.; Catalona, W. J.; Dahl, D. M.; Dall’Era, M.; Davis, J. W.; Drake, B. F.; Epstein, J. I.; Etzioni, R. B.; Farrington, T. A.; Garraway, I. P.; Jarrard, D.; Kauffman, E.; Kaye, D.; Kibel, A. S.; LaGrange, C. A.; Maroni, P.; Ponsky, L.; Reys, B.; Salami, S. S.; Sanchez, A.; Seibert, T. M.; Shaneyfelt, T. M.; Smaldone, M. C.; Sonn, G.; Tyson, M. D. 2nd; Vapiwala, N.; Wake, R.; Washington, S. 3rd; Yu, A.; Yuh, B.; Berardi, R. A.; Freedman-Cass, D. A.
Title: NCCN Guidelines® Insights: Prostate cancer early detection, version 1.2023 Featured updates to the NCCN guidelines
Abstract: The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease. © 2023 Authors. All rights reserved.
Keywords: biopsy; prostatic neoplasms; prostate; prostate tumor; early detection of cancer; procedures; humans; human; male; early cancer diagnosis
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 21
Issue: 3
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2023-03-01
Start Page: 236
End Page: 246
Language: English
DOI: 10.6004/jnccn.2023.0014
PUBMED: 36898362
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sigrid Viktoria Carlsson
    221 Carlsson
Related MSK Work